Form 4: Director Simba Gill Reports Stock Option Grant
Statement of Changes in Beneficial Ownership
Director Simba Gill of Foghorn Therapeutics Inc. reported the acquisition of stock options on June 24, 2026, as per SEC Form 4 filing.
Summary
- Director Simba Gill acquired 28,000 stock options in Foghorn Therapeutics Inc. on June 24, 2026.
- The options have an exercise price of $4.08 and are exercisable starting June 23, 2036.
- These options represent the right to buy 28,000 shares of common stock.
- The options vest in full on the first anniversary of the grant date, contingent on continued service as a director.
- This filing is made under Section 16(a) of the Securities Exchange Act of 1934.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard stock option grant to a director, which is a routine event and does not inherently signal positive or negative performance.
Positives
- Director Simba Gill has been granted stock options, indicating potential future equity ownership and alignment with company performance.
- The grant of 28,000 options suggests a commitment to retaining key leadership personnel.
Risks
- The vesting of options is contingent on continued service, meaning the reporting person could forfeit them if they leave the board.
- The exercise price of $4.08 means the options will only be profitable if the stock price rises above this level.
Future Outlook
The future outlook for these options depends on the company's stock performance. If Foghorn Therapeutics' stock price exceeds $4.08 by June 23, 2036, the options will be profitable for the reporting person.
Industry Context
StockSavvy.ai notes that grants of stock options to directors are a common practice in the biotechnology and pharmaceutical sectors, serving as a standard incentive to align executive and director interests with shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Simba Gill has granted a limited power of attorney to Michael LaCascia, Adrian Gottschalk, and Samantha Macina to execute SEC filings on his behalf. | 2025-12-01 | Facilitates timely and accurate filing of required disclosures by authorized representatives. |
Stakeholder Impact
- Shareholders: The grant of options to a director aligns their interests with shareholders, as the director benefits from an increase in stock price.
- Employees: This filing does not directly impact employees but is part of the broader compensation and governance structure of the company.
Next Steps
- The reporting person may exercise the stock options on or after June 23, 2036, provided the stock price is favorable.
- The options will fully vest on the first anniversary of the grant date, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 2025-12-01 | Date of execution for the Limited Power of Attorney by Simba Gill. |
| 2026-06-23 | Date from which the stock options are exercisable. |
| 2026-06-24 | Transaction date for the acquisition of stock options. |
| 2026-06-25 | Date of signature for the Form 4 filing. |
| 2036-06-23 | Expiration date for the stock options. |
Keywords
Foghorn Therapeutics, FHTX, Form 4, Stock Options, Director, SEC Filing, Beneficial Ownership, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.